To the full analysis
ANI Pharmaceuticals stock: growth
ANIPANI Pharmaceuticals reported $883.37M in revenue for fiscal 2025, up 43.8% on the prior year, up 33.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
24.2%
per year from 2006 to 2025, per share 3.1%
Earnings (Annual rate)
19.2%
per year from 2006 to 2025, per share −1.5%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 33.5% | 27.7% | 24.2% |
| Revenue per share | 20.4% | 20.7% | 3.1% |
| Earnings | no data | 17.7% | 19.2% |
| Earnings per share | no data | 10.1% | −1.5% |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $14.44M | $2.79M | −$5.04M |
| 2007 | $493.05K | −$7.58M | $710.56K |
| 2008 | $3.78M | −$17.43M | −$16.19M |
| 2009 | $1.26M | −$47.53M | −$18.6M |
| 2010 | $2.47M | −$46.2M | −$40.16M |
| 2011 | $435.16K | −$51.61M | −$48.59M |
| 2012 | $2.3M | −$27.72M | −$25.89M |
| 2013 | $30.08M | $301K | −$5.68M |
| 2014 | $55.97M | $28.75M | −$13.72M |
| 2015 | $76.32M | $15.38M | −$15.42M |
| 2016 | $128.62M | $3.93M | −$121.59M |
| 2017 | $176.84M | −$1.08M | −$68.57M |
| 2018 | $201.58M | $15.49M | $56.16M |
| 2019 | $206.55M | $6.09M | $18.08M |
| 2020 | $208.48M | −$22.55M | −$53.06M |
| 2021 | $216.14M | −$42.6M | −$20.32M |
| 2022 | $316.39M | −$47.9M | −$47.66M |
| 2023 | $486.82M | $18.78M | $100.45M |
| 2024 | $614.38M | −$18.52M | $47.06M |
| 2025 | $883.37M | $78.34M | $150.9M |
Revenue by segment
How ANI Pharmaceuticals, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Sales of rare disease pharmaceutical products48%
- Total Sales of Generics and Other45%
- Sales of Established Brands7%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Sales of rare disease pharmaceutical products | $229.6M | $422.65M | 47.8% |
| Total Sales of Generics and Other | $320.03M | $399.41M | 45.2% |
| Sales of Established Brands | $64.74M | $61.31M | 6.9% |
| Total revenue | $614.38M | $883.37M | 100% |
Revenue by region
Where ANI Pharmaceuticals, Inc. generates its revenue.
- United States96%
- Outside the US4%
- Other< 1%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| United States | $211.89M | $312.43M | $486.25M | $604.99M | $852.44M | 96.5% |
| Outside the US | no data | no data | no data | $9.39M | $30.92M | 3.5% |
| Other | $4.24M | $3.96M | $0 | $0 | $0 | 0% |
| Total revenue | $216.14M | $316.39M | $486.82M | $614.38M | $883.37M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Nov 2025)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.